A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
复制标题
DOI：
10.1097/cji.0b013e3181f4c208
复制
发表时间：
2010-11-01
影响因子：
3.9
通讯作者：
Tartour, Eric
中科院分区：
文献类型：
--
作者：
Adotevi, Olivier;Pere, Helene;Tartour, Eric
舒尼替尼是一种抗血管生成分子，是治疗转移性肾细胞癌患者的一线标准治疗药物之一。然而，它只对一个亚组的患者有益，没有发现舒尼替尼疗效的预测标志物。28例转移性肾细胞癌患者接受了舒尼替尼治疗，另一个亚组的7例原发性肾细胞癌患者也接受了舒尼替尼新辅助治疗。在一项前瞻性研究中，在每个治疗周期之前和之后，在血液和肿瘤中测量CD3（+）CD4（+）CD25（hi）Foxp3（+）调节性T细胞（一种免疫抑制细胞群）。我们观察到在每个周期的舒尼替尼治疗后外周血Foxp3（+）调节性T细胞的数量减少。治疗2或3个周期后Foxp3（+）调节性T细胞数量减少的患者的总生存期显著延长（P
Sunitinib, an antiangiogenic molecule, is one of the first-line standard of care in the treatment of patients with metastatic renal cell carcinoma. However, it only benefits to a subgroup of patients and no predictive markers of sunitinib efficacy have been identified. Twenty-eight metastatic renal cell carcinomas were treated with sunitinib-based therapy and another subgroup of 7 primary renal cell cancer patients were also treated by sunitinib in a neoadjuvant trial. Measurements of CD3(+) CD4(+) CD25(hi) Foxp3(+) regulatory T cells, an immunosuppressive cell population, were performed before and after each cycle of treatment in blood and tumor in a prospective study. We observed a decrease in the number of peripheral blood Foxp3(+) regulatory T cells after each cycle of sunitinib-based therapy. The overall survival was significantly longer in patients showing a decrease in the number of Foxp3(+) regulatory T cells after 2 or 3 cycles of treatment (P